NCT06332391 Paced Heart Rate Acceleration for Cardiac Conditioning
| NCT ID | NCT06332391 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Denice Hodgson-Zingman, MD |
| Condition | Heart Failure, Systolic |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2024-06-26 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2024-06-26 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A clinical trial of exercise-similar heart rate acceleration delivered via cardiac pacing vs. sham intervention in subjects at rest will be performed. The study population comprises subjects with guideline-directed medically managed left ventricular dysfunction due to ischemic or non-ischemic cardiomyopathy and an existing implantable cardioverter defibrillator or biventricular implantable cardioverter defibrillator. The purpose of the study is to understand how the heart rate pattern of exercise contributes to the considerable cardiac conditioning effects of exercise and estimate whether the pacing approach may have translational clinical applicability. Fifty-two subjects will be randomized, single-blinded, to either the pacing intervention or a sham intervention which they will receive once daily, 3 days/week for 6 weeks. Baseline symptoms and clinical test results will be compared to the same measures at 2 weeks, 4 weeks and 6 weeks of intervention/sham and at 3 months and one-year post-intervention. The primary endpoint will be the change in left ventricular ejection fraction from baseline in intervention vs. sham groups (mixed effects linear regression with time and treatment arm as fixed effects and pre-specified covariates of sex and cardiomyopathy type as random effects). Secondary endpoints will include changes in quality of life, 6-minute walk distance, cardiopulmonary exercise test (CPET) measures, daily activity and major adverse cardiac events (MACE) at 3 and 12 months between pacing and sham groups. A "dose-response" analysis of outcomes at 2, 4, and 6 weeks of the intervention vs. sham compared with baseline will be performed.
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female sex * Age 18 years or greater * Available transportation for study visits * Left ventricular ejection fraction \< or = 40% despite at least 3 months guideline-directed medial therapy * NYHA class II-III heart failure symptoms * Atrial-lead inclusive implantable cardioverter defibrillator or biventricular defibrillator in place \> 3 months * Intrinsic or biventricular paced QRS duration of \<= 120 milliseconds Exclusion Criteria: * Age \< 18 years * Inability to ambulate safely * Congenital or primary valve disease * Ongoing (not suppressed) atrial arrhythmias * Left ventricular thrombus * Severe peripheral arterial disease that limits mobility * Hospital admission for life-threatening condition (e.g. heart failure, stroke) in the past 3 months * Major surgery in the past 3 months or anticipated during the period of study * Ventricular pacing indication in the absence of biventricular pacing * Life expectancy \< 1 year * Hemodialysis * Hematocrit \< 30% * Severe chronic lung disease that limits activity or requires oxygen * Pregnancy * Implantable cardioverter defibrillator battery longevity \< 1 year * Vulnerable populations such as prisoners and institutionalized individuals
Contact & Investigator
Denice Hodgson-Zingman, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT06332391 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Heart Failure, Systolic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06332391 currently recruiting?
Yes, NCT06332391 is actively recruiting participants. Contact the research team at denice-zingman@uiowa.edu for enrollment information.
Where is the NCT06332391 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06332391 clinical trial?
NCT06332391 is sponsored by Denice Hodgson-Zingman, MD. The principal investigator is Denice Hodgson-Zingman, MD at University of Iowa. The trial plans to enroll 52 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.